Rapid re-expression of retrovirally introduced versusendogenous TCRs in engineered T cells afterantigen-specific stimulation

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 165-174

  Van Loenen, Marleen M ^a   Hagedoorn, Renate S ^a   De Boer, Renate ^a   Van Egmond, Esther H M ^a   Falkenburg, J H Frederik ^a   Heemskerk, Mirjam H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

gene regulation T cell activation; gene therapy; T cells; T cell receptor gene transfer

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; BIOENGINEERING; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INTERNALIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RETROVIRUS; T LYMPHOCYTE;

ANTIGENS, CD3; CELL LINE; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 79953052188     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318206a10c     Document Type: Article

References (58)

1. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519. (Pubitemid 37328742)
2. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999; 163:507-513. (Pubitemid 29295880)
3. Cooper LJ, Kalos M, Lewinsohn DA, et al. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74:8207-8212. (Pubitemid 30641669)
4. Dembic Z, Haas W, Weiss S, et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986;320: 232-238. (Pubitemid 16040238)
5. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102:3530-3540. (Pubitemid 37409367)
6. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T-cell receptor gene transfer. J Exp Med. 2004; 199:885-894. (Pubitemid 38481080)
7. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962-970. (Pubitemid 32976170)
8. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535-546.
9. Kessels HW, Wolkers MC, Van dB, et al. Immunotherapy through TCR gene transfer. Nat Immunol. 2001;2:957-961. (Pubitemid 32976169)
10. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129. (Pubitemid 44547756)
11. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005;106:3062-3067. (Pubitemid 41565901)
12. Cooper LJ, Topp MS, Pinzon C, et al. Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther. 2004;15:648-658. (Pubitemid 38925217)
13. Plavec I, Agarwal M, Ho KE, et al. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther. 1997;4:128-139. (Pubitemid 27096137)
14. Pollok KE, van Der Loo JC, Cooper RJ, et al. Costimulation of transduced T lymphocytes via T-cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum Gene Ther. 1999;10:2221-2236. (Pubitemid 29416301)
15. Paillard F, Sterkers G, Vaquero C. Correlation between up-regulation of lymphokine mRNA and down-regulation of TcR, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes. Biochem Biophys Res Commun. 1992;186:603-611.
16. Paillard F. Activation of retrovirally transduced T lymphocytes. Hum Gene Ther. 1998;9:1395-1396. (Pubitemid 28379078)
17. Lee KH, Dinner AR, Tu C, et al. The immunological synapse balances T-cell receptor signaling and degradation. Science. 2003;302:1218-1222. (Pubitemid 37421028)
18. Schonrich G, Kalinke U, Momburg F, et al. Down-regulation of T-cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell. 1991;65:293-304. (Pubitemid 121006059)
19. Schrum AG, Turka LA, Palmer E. Surface T-cell antigen receptor expression and availability for long-term antigenic signaling. Immunol Rev. 2003;196:7-24. (Pubitemid 37468100)
20. Viola A, Lanzavecchia A. T-cell activation determined by T-cell receptor number and tunable thresholds. Science. 1996;273: 104-106. (Pubitemid 26255435)
21. Andre P, Boretto J, Hueber AO, et al. A dominant-negative mutant of the Rab5 GTPase enhances T-cell signaling by interfering with TCR down-modulation in transgenic mice. J Immunol. 1997;159:5253-5263. (Pubitemid 127470051)
22. Naramura M, Jang IK, Kole H, et al. c-Cbl and Cbl-b regulate T-cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol. 2002;3:1192-1199. (Pubitemid 35469704)
23. Bronstein-Sitton N, Wang L, Cohen L, et al. Expression of the T-cell antigen receptor zeta chain following activation is controlled at distinct checkpoints: implications for cell surface receptor down-modulation and re-expression. J Biol Chem. 1999;274:23659-23665.
24. D'Oro U, Vacchio MS, Weissman AM, et al. Activation of the Lck tyrosine kinase targets cell surface T-cell antigen receptors for lysosomal degradation. Immunity. 1997;7:619-628. (Pubitemid 28156630)
25. Valitutti S, Muller S, Salio M, et al. Degradation of T-cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med. 1997;185:1859-1864. (Pubitemid 27242207)
26. Ruggieri L, Aiuti A, Salomoni M, et al. Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. Hum Gene Ther. 1997;8:1611-1623. (Pubitemid 27455297)
27. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7:1405-1413. (Pubitemid 26293560)
28. Burrows SR, Kienzle N, Winterhalter A, et al. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000;165:6229-6234.
29. Heemskerk MH, Blom B, Nolan G, et al. Inhibition of T-cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med. 1997;186:1597-1602. (Pubitemid 27479820)
30. Van der Veken LT, Hagedoorn RS, van Loenen MM, et al. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res. 2006;66: 3331-3337.
31. Drake DR III, Ream RM, Lawrence CW, et al. Transient loss of MHC class I tetramer binding after CD8+ T-cell activation reflects altered T-cell effector function. J Immunol. 2005;175: 1507-1515. (Pubitemid 41023051)
32. Anikeeva N, Somersalo K, Sims TN, et al. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 2005;102:6437-6442. (Pubitemid 40617461)
33. Green JM, Karpitskiy V, Kimzey SL, et al. Coordinate regulation of T-cell activation by CD2 and CD28. J Immunol. 2000;164:3591-3595. (Pubitemid 30169811)
34. Shaw S, Luce GE, Quinones R, et al. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature. 1986;323:262-264. (Pubitemid 16054312)
35. Call ME, Wucherpfennig KW. Molecular mechanisms for the assembly of the T-cell receptor-CD3 complex. Mol Immunol. 2004;40:1295-1305. (Pubitemid 38456981)
36. Clevers H, Alarcon B, Wileman T, et al. The T-cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol. 1988; 6:629-662. (Pubitemid 19141599)
37. Dietrich J, Kastrup J, Lauritsen JP, et al. TCRzeta is transported to and retained in the Golgi apparatus independently of other TCR chains: implications for TCR assembly. Eur J Immunol. 1999;29:1719-1728. (Pubitemid 29224478)
38. Koning F, Maloy WL, Cohen D, et al. Independent association of T-cell receptor beta and gamma chains with CD3 in the same cell. J Exp Med. 1987;166:595-600. (Pubitemid 17134037)
39. Weissman AM, Frank SJ, Orloff DG, et al. Role of the zeta chain in the expression of the T-cell antigen receptor: genetic reconstitution studies. EMBO J. 1989;8:3651-3656. (Pubitemid 20016043)
40. Bonifacino JS, Suzuki CK, Lippincott-Schwartz J, et al. Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. J Cell Biol. 1989;109:73-83. (Pubitemid 19180120)
41. Huppa JB, Ploegh HL. The alpha chain of the T-cell antigen receptor is degraded in the cytosol. Immunity. 1997;7: 113-122. (Pubitemid 27357269)
42. Wileman T, Carson GR, Concino M, et al. The gamma and epsilon subunits of the CD3 complex inhibit pre-Golgi degradation of newly synthesized T-cell antigen receptors. J Cell Biol. 1990;110:973-986.
43. Rubin B, Llobera R, Gouaillard C, et al. Dissection of the role of CD3gamma chains in profound but reversible T-cell receptor down-regulation. Scand J Immunol. 2000;52:173-183.
44. Brower RC, England R, Takeshita T, et al. Minimal requirements for peptide mediated activation of CD8+ CTL. Mol Immunol. 1994;31:1285-1293. (Pubitemid 24348765)
45. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T-cell activation. Science. 1990;249:1028-1030.
46. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 1990;346:574-576.
47. Sykulev Y, Joo M, Vturina I, et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4:565-571. (Pubitemid 26233310)
48. Demotte N, Colau D, Ottaviani S, et al. A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling. Eur J Immunol. 2002;32:1688-1697. (Pubitemid 34679156)
49. Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T-cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 2008;28: 414-424. (Pubitemid 351335307)
50. Bonefeld CM, Rasmussen AB, Lauritsen JP, et al. TCR comodulation of nonengaged TCR takes place by a protein kinase C and CD3 gamma di-leucine-based motif-dependent mechanism. J Immunol. 2003;171:3003-3009. (Pubitemid 37093523)
51. Exley M, Wileman T, Mueller B, et al. Evidence for multivalent structure of T-cell antigen receptor complex. Mol Immunol. 1995;32:829-839.
52. Niedergang F, Dautry-Varsat A, Alcover A. Peptide antigen or superantigen-induced down-regulation of TCRs involves both stimulated and unstimulated receptors. J Immunol. 1997; 159:1703-1710. (Pubitemid 127484155)
53. San Jose E, Borroto A, Niedergang F, et al. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity. 2000;12: 161-170. (Pubitemid 30398630)
54. Stotz SH, Bolliger L, Carbone FR, et al. T-cell receptor (TCR) antagonism without a negative signal: evidence from T-cell hybridomas expressing two independent TCRs. J Exp Med. 1999;189:253-264.
55. Valitutti S, Muller S, Cella M, et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 1995;375:148-151.
56. Burns WR, Zheng Z, Rosenberg SA, et al. Lack of specific (gamma)-retroviral vector LTR promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood. 2009; 114:2888-2899.
57. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
58. Van Loenen MM, Hagedoorn RS, Kester MG, et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res. 2009;69:2034-2041.